Targeting the key cholesterol biosynthesis enzyme squalene monooxygenasefor cancer therapy

Area of Science:

• Biochemistry
• Oncology
• Molecular Biology

Background:

• Cholesterol metabolism plays a critical role in cellular processes, and its dysregulation is a hallmark of cancer.
• Squalene monooxygenase (SQLE) is identified as the second rate-limiting enzyme in the cholesterol biosynthesis pathway.
• Aberrant SQLE expression and activity are increasingly recognized in various cancer types, influencing tumor development.

Purpose of the Study:

• To provide a comprehensive overview of the multifaceted role of SQLE in cancer initiation and progression.
• To elucidate the regulatory mechanisms governing SQLE expression and function within the context of oncogenesis.
• To summarize recent advancements in the development of SQLE-targeting antitumor therapies.

Main Methods:

• Literature review of preclinical and clinical studies on SQLE in cancer.
• Analysis of genetic and molecular data linking SQLE to cancer phenotypes.
• Synthesis of information on emerging therapeutic strategies targeting SQLE.

Main Results:

• SQLE dysregulation is a significant driver of cancer initiation and progression across multiple tumor types.
• Evidence supports SQLE's involvement in key oncogenic pathways, including proliferation and survival.
• Several therapeutic approaches targeting SQLE are under investigation, showing promising preclinical antitumor activity.

Conclusions:

• SQLE is a critical regulator of cholesterol metabolism in cancer and represents a viable therapeutic target.
• Targeting SQLE offers a promising strategy for the development of novel anticancer treatments.
• Further research into SQLE regulation and targeted therapies is warranted to combat cancer effectively.